Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 6—June 2022
Research

Effect of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo

Neil RupaniComments to Author , Mbong Eta Ngole, J. Austin Lee, Adam R. Aluisio, Monique Gainey, Shiromi M. Perera, Lina Kashibura Ntamwinja, Ruffin Mbusa Matafali, Rigo Fraterne Muhayangabo, Fiston Nganga Makoyi, Razia Laghari, Adam C. Levine, and Alexis S. Kearney
Author affiliations: Brown University, Providence, Rhode Island, USA (N. Rupani, J.A. Lee, A.R. Aluisio, A.C. Levine, A.S. Kearney); International Medical Corps, Goma, Democratic Republic of the Congo (M.E. Ngole, L.K. Ntamwinja, R.M. Matafali, R.F. Muhayangabo, F.N. Makoyi, R. Laghari); Rhode Island Hospital, Providence (M. Gainey); International Medical Corps, Washington, DC, USA (S.M. Perera)

Main Article

Table 1

Patient characteristics for study of the effect of recombinant vesicular stomatitis virus–Zaire Ebola virus vaccination on Ebola virus disease illness and death, Democratic Republic of the Congo*

Characteristic Overall, n = 385 Not vaccinated, n = 248 Vaccinated, n = 137 p value†
Age, y 26.0 (18.0‒40.0) 25.5 (12.0‒40.0) 28.0 (20.0‒40.0) 0.044
<5 49 (12.7) 43 (17.3) 6 (4.4) 0.001
5‒15 34 (8.8) 26 (10.5) 8 (5.8)
16‒25 101 (26.2) 55 (22.2) 46 (33.6)
26‒35 88 (22.9) 54 (21.8) 34 (24.8)
36‒45 38 (9.9) 19 (7.6) 19 (13.9)
46‒55 41 (10.7) 27 (10.9) 14 (10.2)
>55
34 (8.8)
24 (9.7)
10 (7.3)

Sex 0.018
M 159 (41.3) 91 (36.7) 68 (49.6)
F
226 (58.7)
157 (63.3)
69 (50.4)

Province 0.002
North Kivu 235 (61.0) 142 (57.3) 93 (67.9)
Ituri 142 (36.9) 104 (41.9) 38 (27.7)
Unknown
8 (2.1)
2 (0.8)
6 (4.4)

Known or suspected Ebola contact <0.001
No 73 (19.0) 62 (25.0) 11 (8.0)
Yes 220 (57.1) 130 (52.4) 90 (65.7)
Unknown
92 (23.9)
56 (22.6)
36 (26.3)

Days between symptom onset and admission, d
4.0 (2.0‒6.0)
5.0 (3.0‒7.0)
2.0 (1.0‒4.0)
<0.001
First cycle threshold value
21.6 (18.2‒26.2)
20.4 (17.7‒24.2)
24.6 (19.9‒28.1)
<0.001
Therapeutic received 0.005
None 65 (16.9) 53 (21.4) 12 (8.8)
Zmapp or Remdesivir 76 (19.7) 46 (18.5) 30 (21.9)
mAb114 or REGN-EB3
244 (63.4)
149 (60.1)
95 (69.3)

Final outcome <0.001
Died 191 (49.6) 157 (63.3) 34 (24.8)
Survived
194 (50.4)
91 (36.7)
103 (75.2)

Length of stay among survivors, d 21.0 (18.0‒26.0), n = 193 22.0 (19.0‒28.5), n = 91 20.0 (17.0‒23.8), n = 102 0.004

*Values are median (IQR) or no. (%) . IQR, interquartile range; MAb, monoclonal antibody. †Statistical tests were performed by using the Wilcoxon rank sum test, the Pearson χ2 test, and the Fisher exact test. Boldface indicates a significant difference (p<0.05).

Main Article

Page created: March 31, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external